Merus Bio News and Activities

Merus Bio is owned by Genmab.

Genmab is one of the...

• Forbes Global 2000 (#1542);
• Stoxx 600;
• TOB Iconic 10,000.

Genmab is a company listed under the stock ticker GMAB (DK).

Genmab has a direct presence in 4 countries.

Genmab has 4 subsidiaries including Genmab Europe, Genmab Japan and Genmab USA.

Acquisition, funding and merger involving Genmab.

• Genmab has acquired Merus Bio (posted on December 30 2025).
• Genmab has announced the acquisition of Merus Bio  (posted on October 27 2025).

View the org chart displaying its 15 main executives

Most searched biographies at Merus Bio

• Jan Van De Winkel, Executive Director and Chief Executive Officer
• Martine Van Vugt, Non-Executive Director
• Anthony Pagano, Non-Executive Director

Popular executive movements at Merus Bio

• Robert Doornbos, Vice President, Manufacturing and Non-Clinical Development, has left the company  (posted on April 3 2026).
• Cecile Geuijen, Senior Vice President and Chief Scientific Officer, has left the company  (posted on April 3 2026).
• Audrey Bergan, Chief People Officer, has left the company  (posted on April 3 2026).

Click here to view some more movements at Merus Bio

Popular executive movements at Genmab

• Robert Doornbos has joined the company as Vice President, Head of Chemistry, Manufacturing and Controls Product Development  (posted on April 3 2026).
• Margarida Duarte has joined the company as General Manager, Europe and Emerging Markets  (posted on April 3 2026).

Create your alert
to follow the executive moves at Merus Bio.

Genmab has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Merus Bio

• Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - Merus
• Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab - Merus
• Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety - Merus
• Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Merus
• Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Merus
• Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - Merus
• Merus to Present at the 2025 Wells Fargo Healthcare Conference - Merus
• Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update - Merus
• Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Merus
• Merus to Present at the Canaccord Genuity 45th Annual Growth Conference - Merus
• View more press releases Close

Social media about Merus Bio

• Merus Bio on Wikipedia, Google News & Yahoo Finance
• Merus Bio on LinkedIn, X (Twitter) & YouTube